Perspective Therapeutics FY2025 EPS Reduced by B. Riley

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Equities researchers at B. Riley reduced their FY2025 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued on Monday, November 17th. B. Riley analyst Y. Zhi now forecasts that the company will post earnings per share of ($1.27) for the year, down from their previous estimate of ($1.21). B. Riley has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Perspective Therapeutics’ Q4 2025 earnings at ($0.37) EPS.

Several other brokerages have also recently commented on CATX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Friday, October 3rd. BTIG Research began coverage on Perspective Therapeutics in a report on Friday, October 10th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, November 11th. Four investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and an average price target of $11.78.

Perspective Therapeutics Trading Up 0.9%

Shares of NYSEAMERICAN:CATX opened at $2.30 on Thursday. The firm has a fifty day moving average price of $3.18 and a 200 day moving average price of $3.31. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 15.09 and a current ratio of 15.09.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth about $46,000. Ground Swell Capital LLC bought a new stake in Perspective Therapeutics in the second quarter worth about $56,000. Los Angeles Capital Management LLC purchased a new position in shares of Perspective Therapeutics during the second quarter valued at approximately $61,000. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of Perspective Therapeutics by 81.8% during the third quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after buying an additional 13,168 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.